Overview

Oral Cyclosporine in Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, placebo-controlled trial of oral Cyclosporine A (CsA) in patients with advanced stage chronic obstructive pulmonary disease. The purpose of the study is to evaluate the safety and effectiveness of CsA as a therapy for the adaptive immune response in advanced stage Chronic Obstructive Pulmonary Disease (COPD). Subjects between 45 and 80 years of age with a confirmed diagnosis of advanced stage COPD, not responsive to conventional inhaler therapy, who meet all the study requirements, will be enrolled in this study. A total of 30 subjects of either sex will be enrolled in this study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Michael Donahoe
University of Pittsburgh
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Cyclosporine
Cyclosporins